Microbot Medical, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US59503A2042
USD
2.46
0.25 (11.31%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

5.03 M

Shareholding (Mar 2025)

FII

0.65%

Held by 15 FIIs

DII

96.22%

Held by 3 DIIs

Promoter

0.00%

How big is Microbot Medical, Inc.?

22-Jun-2025

As of Jun 18, Microbot Medical, Inc. has a market capitalization of 88.03 million, with net sales of 0.00 million and a net profit of -11.66 million over the latest four quarters. Shareholder's funds are 3.53 million, and total assets are 6.03 million as of Dec 24.

As of Jun 18, Microbot Medical, Inc. has a market capitalization of 88.03 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -11.66 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 3.53 million and Total Assets of 6.03 million.

Read More

What does Microbot Medical, Inc. do?

22-Jun-2025

Microbot Medical, Inc. is a pre-clinical medical device company specializing in robotic endoluminal surgery devices, with a market cap of USD 88.03 million and a recent net profit of -3 million. The company operates in the Pharmaceuticals & Biotechnology industry and currently does not pay dividends.

Overview:<BR>Microbot Medical, Inc. is a pre-clinical medical device company focused on the research, design, and development of robotic endoluminal surgery devices in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 88.03 Million.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 88.03 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.05 <BR>Return on Equity: -40.32% <BR>Price to Book: 3.04<BR><BR>Contact Details:<BR>Address: 25 RECREATION PARK DR SUITE 108, HINGHAM MA : 02043 <BR>Tel: 1 908 9385561 <BR>Fax: 1 302 6555049 <BR>Website: http://www.microbotmedical.com/

Read More

Who are in the management team of Microbot Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Microbot Medical, Inc. is led by Mr. Harel Gadot, who is the Chairman, President, and CEO, alongside independent directors Mr. Yoseph Bornstein, Mr. Scott Burell, Mr. Prattipati Laxminarain, Mr. Martin Madden, and Ms. Aileen Stockburger.

As of March 2022, the management team of Microbot Medical, Inc. includes Mr. Harel Gadot, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features several independent directors: Mr. Yoseph Bornstein, Mr. Scott Burell, Mr. Prattipati Laxminarain, Mr. Martin Madden, and Ms. Aileen Stockburger. <BR><BR>In summary, as of March 2022, the key members of the management team are Mr. Harel Gadot and a group of independent directors, including Mr. Yoseph Bornstein, Mr. Scott Burell, Mr. Prattipati Laxminarain, Mr. Martin Madden, and Ms. Aileen Stockburger.

Read More

Is Microbot Medical, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Microbot Medical, Inc. shows a bullish technical trend, supported by positive MACD and On-Balance Volume indicators, with a year-to-date return of 175.89% compared to the S&P 500's 12.22%.

As of 3 September 2025, the technical trend for Microbot Medical, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The Bollinger Bands indicate a mildly bullish stance on both weekly and monthly time frames. The daily moving averages are also mildly bullish. However, the KST shows a mildly bearish trend on the weekly but bullish on the monthly, and Dow Theory indicates a mildly bearish trend on the weekly and mildly bullish on the monthly. The On-Balance Volume is bullish for both weekly and monthly periods.<BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 175.89% compared to the S&P 500's 12.22%, and over the past year, it has returned 233.91% against the S&P 500's 17.14%. Overall, the current technical stance is bullish, driven primarily by the positive MACD and OBV indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 205 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.07

stock-summary
Return on Equity

-41.86%

stock-summary
Price to Book

6.75

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-4 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-30.51%
0%
-30.51%
6 Months
-9.89%
0%
-9.89%
1 Year
143.56%
0%
143.56%
2 Years
90.7%
0%
90.7%
3 Years
-45.45%
0%
-45.45%
4 Years
-47.99%
0%
-47.99%
5 Years
-66.62%
0%
-66.62%

Microbot Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-22.49%
EBIT to Interest (avg)
-10.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.05
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.50%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.53
EV to EBIT
-5.86
EV to EBITDA
-5.90
EV to Capital Employed
-51.45
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-40.32%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 4 Schemes (3.13%)

Foreign Institutions

Held by 15 Foreign Institutions (0.65%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -40.00% vs -8.70% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-2.50",
          "chgp": "-48.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-2.50",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.54% vs 18.94% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.50",
          "val2": "-9.70",
          "chgp": "-18.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.40",
          "val2": "-10.70",
          "chgp": "-6.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.70
-2.50
-48.00%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.50
-2.50
-40.00%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -40.00% vs -8.70% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.50
-9.70
-18.56%
Interest
0.00
0.00
Exceptional Items
0.00
-1.10
100.00%
Consolidate Net Profit
-11.40
-10.70
-6.54%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.54% vs 18.94% in Dec 2023

stock-summaryCompany CV
About Microbot Medical, Inc. stock-summary
stock-summary
Microbot Medical, Inc.
Pharmaceuticals & Biotechnology
Microbot Medical Inc. is a pre-clinical medical device company. The Company is focused on the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Its technological platforms, ViRob, TipCAT and Liberty, including certain CardioSert assets, are comprised of proprietary technologies. Using the ViRob platform, Microbot is developing the Self Cleaning Shunt (SCSTM) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH). Utilizing the Liberty and CardioSert platforms, it is developing disposable robot for various endovascular interventional procedures. ViRob technology is an autonomous crawling micro-robot. TipCAT is a disposable self-propelled locomotive device. Liberty is a disposable robotic system.
Company Coordinates stock-summary
Company Details
25 RECREATION PARK DR SUITE 108 , HINGHAM MA : 02043
Registrar Details